Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-alpha-naltrexol is a metabolite of the opioid antagonist naltrexone. It functions as a competitive antagonist at opioid receptors, with its highest affinity for the mu-type opioid receptor (MOR). In pharmacological studies, particularly in non-human primates, 6-alpha-naltrexol has been shown to produce effects qualitatively similar to naltrexone, such as substituting for naltrexone in drug discrimination tasks and precipitating withdrawal in morphine-dependent subjects. However, it is significantly less potent than its parent compound. It is primarily utilized as a research tool to investigate the constitutive activity of opioid receptors and the comparative pharmacology of naltrexone metabolites.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-alpha-naltrexol.